retatrutide trial VisualAbstract: reduces body weight by 17.5% in patients with obesity ESC 2024: Retatrutide improves lipid

The best protocol is not simply the one with the highest dose

A study from the Employee Benefit Research Institute (EBRI), supported by the Blue Cross Blue Shield Association and other partners, estimates that GLP-1 coverage would be a major premium driver for employer-provided coverage

Shapely can help patients access self-pay programs for FDA-approved medications, such as Wegovy through NovoCare and Zepbound through Lilly Direct, which may offer discounted pricing for eligible patients

Translated by SuperSmart march 12 2026 I'm on my second bottle

By law, any form of bodily introduction of this product into humans or animals is strictly prohibited

Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review